The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
August 19th 2025
The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.
What are Key Considerations When Launching a Rare Disease Drug in a Specialty-Naive Market?
February 28th 2018Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, speaks about the many considerations that have to be addressed when launching a novel rare disease drug in a specialty-naive market.
Watch